Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus
- 3 July 2015
- journal article
- research article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 129 (7) , 533-545
Abstract
Mineralocorticoid receptors (MRs), which are activated by mineralocorticoids and glucocorticoids, actively participate in mechanisms that affect the structure and function of blood vessels. Although experimental and clinical evidence shows that vascular damage in diabetes is associated with structural alterations in large and small arteries, the role of MR in this process needs further studies. Thus, we tested the hypothesis that MR, through redox-sensitive mechanisms, plays a role in diabetes-associated vascular remodelling. Male, 12–14-weeks-old db/db mice, a model of type 2 diabetes and their non-diabetic counterpart controls (db/+) were treated with spironolactone (MR antagonist, 50 mg/kg/day) or vehicle for 6 weeks. Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice. In addition, spironolactone significantly reduced serum insulin levels, but not aldosterone levels in diabetic mice. Insulin sensitivity, evaluated by the HOMA (homoeostatic model assessment)-index, was improved in spironolactone-treated diabetic mice. Mesenteric resistance arteries from vehicle-treated db/db mice exhibited inward hypertrophic remodelling, increased number of smooth muscle cells and increased vascular stiffness. These structural changes, determined by morphometric analysis and with a myography for pressurized arteries, were prevented by spironolactone treatment. Arteries from vehicle-treated db/db mice also exhibited augmented collagen content, determined by Picrosirius Red staining and Western blotting, increased reactive oxygen species (ROS) generation, determined by dihydroethidium (DHE) fluorescence, as well as increased expression of NAD(P)H oxidases 1 and 4 and increased activity of mitogen-activated protein kinases (MAPKs). Spironolactone treatment prevented all these changes, indicating that MR importantly contributes to diabetes-associated vascular dysfunction by inducing oxidative stress and by increasing the activity of redox-sensitive proteins.Keywords
This publication has 40 references indexed in Scilit:
- Aldosterone and angiotensin: Role in diabetes and cardiovascular diseasesEuropean Journal of Pharmacology, 2012
- Type 2 Diabetes Mellitus: A Review of Current TrendsOman Medical Journal, 2012
- Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound HealingInternational Journal of Vascular Medicine, 2012
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant HypertensionAnnals of Internal Medicine, 2009
- Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapiesCardiovascular Research, 2008
- Reactive oxygen species and vascular remodelling in hypertension: Still aliveCanadian Journal of Cardiology, 2006
- Diabetes mellitus and its treatmentInternational Journal of Diabetes and Metabolism, 2005
- Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathyDiabetes & Metabolism, 2004
- Vascular targets of redox signalling in diabetes mellitusDiabetologia, 2002